Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNB1618 and SYNB1934 in PKU
NCT04534842Phase 2Completed
- Sponsor
- Synlogic
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of labafenogene marselecobac, SYNB1618 in phenylketonuria (PKU), sponsored by Synlogic. Started Aug 2020; status: completed.
02
Drugs
labafenogene marselecobacSYNB1618
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT04534842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534842.